Gilead GS-5829 BET inhibitor mCRPC trial

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Gilead GS-5829 BET inhibitor mCRPC trial

posted on Oct 01, 2016 09:51PM

Gilead has a trial underway for their BET inhibitor GS-5829 for metastatic castrate-resistant prostate cancer (mCRPC) that is also investigating synergy with enzalutamide. The Gilead study is listed as having a study start date of December 2015, whereas the Zenith trial is listed as starting in April 2016. Zenith didn't start dosing until June 15, 2016. This Gilead trial is the only other BET inhibitor trial focused on mCRPC other than Zenith. It will be interesting to follow this development.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer